Understand · Treat · Recover

Myelodysplastic and Myeloproliferative Neoplasms

These are clonal marrow diseases with very different patterns. Low counts, high counts and scarring need distinct explanations.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 12 of 20 · E · Other important blood disorders

MDS: ineffective blood production

Myelodysplastic neoplasms, often still called myelodysplastic syndromes or MDS, produce abnormal blood cells and commonly cause low counts. Fatigue, infection and bleeding may follow. Diagnosis uses blood and marrow findings, chromosome and gene tests, and exclusion of alternatives such as nutritional deficiencies or drug effects. MDS is a blood cancer, but its pace ranges from slow disease to high-risk illness with a greater chance of progression to AML.

Risk-adapted treatment for MDS

Risk assessment combines counts, marrow blasts and chromosome or gene findings. Lower-risk care may focus on anemia, transfusions and selected medicines such as erythropoiesis-stimulating agents, luspatercept or lenalidomide in appropriate biological settings. Higher-risk disease may need hypomethylating treatment, a trial or transplant assessment. Allogeneic transplantation offers a possibility of cure for selected patients but has substantial risks. Regular review checks both symptoms and evolution of disease.

Polycythemia vera and essential thrombocythemia

Polycythemia vera (PV) produces excess red cells; essential thrombocythemia (ET) produces excess platelets. Diagnosis requires more than an isolated raised count. JAK2, CALR or MPL testing is useful in the appropriate disorder, with marrow and other findings. PV is typically JAK2-associated. Dehydration, iron deficiency, inflammation and other causes can mimic parts of the picture. Both PV and ET can cause blood clots; very high platelet counts can sometimes be associated with bleeding rather than protection from it.

Controlling clotting risk

Treatment considers age, previous clots, symptoms, blood counts and other risk factors. PV often uses supervised venesection, which removes blood, and selected patients receive medicines to reduce cell production. Antiplatelet treatment is appropriate for many but not all patients. ET may require observation, antiplatelet therapy or cell-reducing medicines. Do not self-start aspirin: bleeding risks, including acquired von Willebrand problems with extreme thrombocytosis, require assessment.

Myelofibrosis

Myelofibrosis involves marrow scarring and abnormal blood production. It may arise on its own or follow PV or ET. Symptoms can include anemia, an enlarged spleen, sweats, weight loss and fatigue. JAK inhibitors can improve selected symptoms and spleen enlargement; anemia-directed treatment and transfusions may also be needed. Allogeneic transplant is a potentially curative option for selected patients, whereas many drug treatments aim for control and quality of life.

Progression, monitoring and urgent symptoms

Not everyone with MDS or an MPN develops acute leukemia. Monitoring is risk-based and includes count trends, symptoms and sometimes repeat marrow or genetic testing. MDS/MPN overlap diseases, such as CMML, require their own classification. Sudden chest pain, breathlessness, one-sided weakness, speech difficulty, severe headache or a swollen painful leg needs emergency evaluation for clotting. Significant bleeding or fever with low infection-fighting counts also needs urgent care.

Take-home message

Ask for the precise diagnosis, risk category and purpose of each treatment.

Common questions

Does every high platelet count mean ET?

No. Iron deficiency, infection and inflammation are common alternatives. Persistent unexplained elevation needs assessment.

Does MDS always become AML?

No. Progression risk varies substantially and is one reason for individualized follow-up.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.